FDA 483 OBSERVATION · #9 OF 1,923 MOST-CITED
Manufacturing, processing, packing, holding - Controls
FDA cited this observation 1,397 times across 1,246 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
The controls over manufacturing, processing, packing, and holding operations were inadequate to prevent contamination or ensure the product is safe and made under controlled conditions — covering process controls, sanitation during production, and protection of product.
Why FDA writes it — These are the core in-process controls that keep product safe and consistent as it is made and held. Weak controls at this stage let contamination, mix-ups, or process failures reach the product directly, which is why it is a high-frequency, high-consequence finding in food operations especially.
- Conduct manufacturing, processing, packing, and holding operations under conditions and controls that prevent contamination and adulteration.
- Control the process parameters that matter for safety and quality, and monitor them at an adequate frequency.
- Protect product, food-contact surfaces, and packaging from contamination throughout the operation.
- Document the controls and any corrective actions when conditions go out of control.
- Process controls defined on paper but not monitored at an adequate frequency during actual production.
- Product left inadequately protected during holding or transfer steps between controlled operations.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 0.9× the rate of the average FDA-cited firm (7.0% vs 7.8%), across 1,246 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
You did not conduct operations under conditions and controls necessary to minimize the potential for allergen cross-contact.
You did not conduct operations under conditions and controls necessary to minimize the potential for contamination of food and deterioration of food.
You did not conduct operations under conditions and controls necessary to minimize the potential for contamination of food.
You did not conduct operations under conditions and controls necessary to minimize the potential for allergen cross-contact and contamination of food.
You did not conduct operations under conditions and controls necessary to minimize the potential for contamination of food.
You did not conduct operations under conditions and controls necessary to minimize the potential for growth or survival of microorganisms.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →